ofirmev Drug Patent Profile
✉ Email this page to a colleague
When do Ofirmev patents expire, and what generic alternatives are available?
Ofirmev is a drug marketed by Mallinckrodt Hosp and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has four patent family members in three countries.
The generic ingredient in OFIRMEV is acetaminophen. There are sixty-six drug master file entries for this compound. Ninety-four suppliers are listed for this compound. Additional details are available on the acetaminophen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ofirmev
A generic version of ofirmev was approved as acetaminophen by PERRIGO on February 25th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ofirmev?
- What are the global sales for ofirmev?
- What is Average Wholesale Price for ofirmev?
Summary for ofirmev
International Patents: | 4 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 179 |
Clinical Trials: | 60 |
Patent Applications: | 3,689 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ofirmev |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ofirmev |
What excipients (inactive ingredients) are in ofirmev? | ofirmev excipients list |
DailyMed Link: | ofirmev at DailyMed |
![ofirmev drug patent expirations Drug patent expirations by year for ofirmev](/p/graph/s/t/ofirmev-patent-expirations.png)
![Drug Prices for ofirmev](/p/graph/drug-price/ofirmev.png)
Recent Clinical Trials for ofirmev
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Beth Israel Deaconess Medical Center | Phase 3 |
National Institute on Aging (NIA) | Phase 3 |
Nevakar, Inc | Phase 2 |
Paragraph IV (Patent) Challenges for OFIRMEV
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
OFIRMEV | Injection | acetaminophen | 1000 mg/100 mL (10 mg/mL) | 022450 | 1 | 2011-04-07 |
US Patents and Regulatory Information for ofirmev
ofirmev is protected by five US patents.
Patents protecting ofirmev
Reduced dose intravenous acetaminophen
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
Reduced dose intravenous acetaminophen
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN
Reduced dose intravenous acetaminophen
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Reduced dose intravenous acetaminophen
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Reduced dose intravenous acetaminophen
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ofirmev
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ofirmev
See the table below for patents covering ofirmev around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 330136 | Stable liquid paracetamol compositions comprising polyhydric or water soluble alcanol and buffering agent, and further containing a free radical antagonist or scavenger | ⤷ Sign Up |
Australia | 6612001 | ⤷ Sign Up | |
Japan | 2010163462 | NOVEL STABLE LIQUID PARACETAMOL COMPOSITION AND METHOD FOR PRODUCING THE SAME | ⤷ Sign Up |
Poland | 193104 | ⤷ Sign Up | |
Portugal | 858329 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 9805314 | ⤷ Sign Up | |
African Regional IP Organization (ARIPO) | 9801223 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |